BlossomHill Therapeutics, Inc.

Healthcare · Biotechnology · United States

Last price 15.21 USD (Oct 29, 2026, 4:00 PM EDT) · Market cap 483.45M

Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports

BlossomHill Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops small molecule medicines that address medical needs in cancer treatment. Its pipeline includes BH-30643, an OMNI-EGFR inhibitor in clinical development for advanced EGFR-mutant non-small cell lung cancer (NSCLC), BH-501284, and BH-30236, a macrocyclic CLK (Cdc2-like kinase) inhibitor being evaluated in patients with relapsed or refractory acute myeloid leukemia (R/R AML) and higher-risk myelodysplastic syndrome (HR-MDS). BlossomHill Therapeutics, Inc. was incor...